IL171987A - Use of fumaric acid derivatives for preparing a drug for treating or prevention of cardiac insufficiency, myocardial infarct and angina pectoris - Google Patents
Use of fumaric acid derivatives for preparing a drug for treating or prevention of cardiac insufficiency, myocardial infarct and angina pectorisInfo
- Publication number
- IL171987A IL171987A IL171987A IL17198705A IL171987A IL 171987 A IL171987 A IL 171987A IL 171987 A IL171987 A IL 171987A IL 17198705 A IL17198705 A IL 17198705A IL 171987 A IL171987 A IL 171987A
- Authority
- IL
- Israel
- Prior art keywords
- fumaric acid
- drug
- prevention
- preparing
- acid derivatives
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 206010002383 Angina Pectoris Diseases 0.000 title abstract 2
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title abstract 2
- 150000002237 fumaric acid derivatives Chemical class 0.000 title abstract 2
- 208000010125 myocardial infarction Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- FSQQTNAZHBEJLS-OWOJBTEDSA-N (e)-4-amino-4-oxobut-2-enoic acid Chemical class NC(=O)\C=C\C(O)=O FSQQTNAZHBEJLS-OWOJBTEDSA-N 0.000 abstract 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- BSSNZUFKXJJCBG-OWOJBTEDSA-N (e)-but-2-enediamide Chemical class NC(=O)\C=C\C(N)=O BSSNZUFKXJJCBG-OWOJBTEDSA-N 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 206010024119 Left ventricular failure Diseases 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 abstract 1
- 229960004419 dimethyl fumarate Drugs 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- -1 ester salts Chemical class 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 208000028867 ischemia Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000010410 reperfusion Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10341530 | 2003-09-09 | ||
| DE10360869A DE10360869A1 (de) | 2003-09-09 | 2003-12-23 | Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma |
| PCT/EP2004/009835 WO2005023241A1 (en) | 2003-09-09 | 2004-09-03 | The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL171987A0 IL171987A0 (en) | 2006-04-10 |
| IL171987A true IL171987A (en) | 2010-12-30 |
Family
ID=34258515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL171987A IL171987A (en) | 2003-09-09 | 2005-11-15 | Use of fumaric acid derivatives for preparing a drug for treating or prevention of cardiac insufficiency, myocardial infarct and angina pectoris |
Country Status (11)
| Country | Link |
|---|---|
| JP (3) | JP2008529959A (pt) |
| CN (2) | CN102058574B (pt) |
| AT (1) | ATE447946T1 (pt) |
| CY (1) | CY1107849T1 (pt) |
| DE (2) | DE10360869A1 (pt) |
| IL (1) | IL171987A (pt) |
| NZ (1) | NZ543708A (pt) |
| PT (1) | PT1663197E (pt) |
| RS (1) | RS51881B (pt) |
| RU (2) | RU2459621C2 (pt) |
| ZA (1) | ZA200601985B (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2334378B1 (en) | 2008-08-19 | 2014-04-09 | XenoPort, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
| HK1252751A1 (en) * | 2009-01-09 | 2019-05-31 | Fwp Ip Aps | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| CN109044985A (zh) * | 2009-01-09 | 2018-12-21 | 前进制药知识产权有限公司 | 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂 |
| EP2782561A1 (en) * | 2011-11-24 | 2014-10-01 | Synthon BV | Controlled release particles comprising dimethyl fumarate |
| MX370785B (es) * | 2012-02-07 | 2020-01-06 | Biogen Ma Inc | Composiciones farmacéuticas que contienen fumarato de dimetilo. |
| AU2013305684B2 (en) | 2012-08-22 | 2016-11-24 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| JP2015527372A (ja) | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| KR101379427B1 (ko) * | 2013-02-13 | 2014-03-28 | 경북대학교병원 | 디메틸푸마레이트를 유효성분으로 포함하는 신섬유증의 예방 또는 치료용 조성물 |
| WO2014160633A1 (en) | 2013-03-24 | 2014-10-02 | Xenoport, Inc. | Pharmaceutical compositions of dimethyl fumarate |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| EP3041467A1 (en) | 2013-09-06 | 2016-07-13 | XenoPort, Inc. | Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use |
| WO2015042294A1 (en) * | 2013-09-18 | 2015-03-26 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5242905A (en) * | 1987-09-04 | 1993-09-07 | Dexter Chemical Corporation | Pharmaceutical compositions for the treatment of psoriasis |
| US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| AU5474198A (en) * | 1996-12-24 | 1998-07-17 | National Research Council Of Canada | Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals |
| DE19721099C2 (de) * | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| DE19814358C2 (de) * | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
| DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| EE05472B1 (et) * | 2001-01-12 | 2011-10-17 | Fumapharm Ag | Fumaarhappeamiidide kasutamine ravimina |
| RU2189813C1 (ru) * | 2001-06-01 | 2002-09-27 | Российский научно-исследовательский институт гематологии и трансфузиологии | Лекарственное средство антигипоксического действия |
| DE10217314A1 (de) * | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
-
2003
- 2003-12-23 DE DE10360869A patent/DE10360869A1/de not_active Withdrawn
-
2004
- 2004-09-03 CN CN2010102746278A patent/CN102058574B/zh not_active Expired - Fee Related
- 2004-09-03 NZ NZ543708A patent/NZ543708A/en unknown
- 2004-09-03 JP JP2006515290A patent/JP2008529959A/ja active Pending
- 2004-09-03 CN CN2004800217249A patent/CN1829505B/zh not_active Expired - Fee Related
- 2004-09-03 PT PT04764790T patent/PT1663197E/pt unknown
- 2004-09-03 RS YU20050948A patent/RS51881B/sr unknown
- 2004-09-03 AT AT07121903T patent/ATE447946T1/de not_active IP Right Cessation
- 2004-09-03 DE DE602004024143T patent/DE602004024143D1/de not_active Expired - Lifetime
-
2005
- 2005-11-15 IL IL171987A patent/IL171987A/en not_active IP Right Cessation
-
2006
- 2006-03-08 ZA ZA200601985A patent/ZA200601985B/en unknown
-
2007
- 2007-10-15 RU RU2007138216/15A patent/RU2459621C2/ru not_active IP Right Cessation
-
2008
- 2008-01-08 CY CY20081100024T patent/CY1107849T1/el unknown
-
2009
- 2009-12-24 JP JP2009292569A patent/JP5784877B2/ja not_active Expired - Fee Related
-
2012
- 2012-04-19 RU RU2012115860/15A patent/RU2012115860A/ru not_active Application Discontinuation
-
2015
- 2015-06-04 JP JP2015113701A patent/JP2015155480A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004024143D1 (de) | 2009-12-24 |
| RU2459621C2 (ru) | 2012-08-27 |
| CN1829505B (zh) | 2010-11-10 |
| CN1829505A (zh) | 2006-09-06 |
| RU2012115860A (ru) | 2013-10-27 |
| HK1094650A1 (en) | 2007-04-04 |
| RS51881B (sr) | 2012-02-29 |
| JP5784877B2 (ja) | 2015-09-24 |
| PT1663197E (pt) | 2007-12-26 |
| JP2015155480A (ja) | 2015-08-27 |
| ZA200601985B (en) | 2007-05-30 |
| DE10360869A1 (de) | 2005-04-07 |
| RU2007138216A (ru) | 2009-04-20 |
| JP2008529959A (ja) | 2008-08-07 |
| IL171987A0 (en) | 2006-04-10 |
| CY1107849T1 (el) | 2013-06-19 |
| NZ543708A (en) | 2008-11-28 |
| CN102058574A (zh) | 2011-05-18 |
| CN102058574B (zh) | 2013-02-13 |
| ATE447946T1 (de) | 2009-11-15 |
| JP2010070563A (ja) | 2010-04-02 |
| RS20050948A (sr) | 2008-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107849T1 (el) | Η χρηση παραγωγων φουμαρικου οξεος για θεραπεια καρδιακης ανεπαρκειας και ασθματος | |
| ES2356883B1 (es) | Composición para el tratamiento del dolor y/o la inflamación. | |
| US6632962B2 (en) | Caspase inhibitors and uses thereof | |
| EA200101166A1 (ru) | Ингибиторы металлопротеаз | |
| EA201170607A1 (ru) | Акриламидопроизводные, применимые как ингибиторы перехода митохондриальной проницаемости | |
| BG106343A (bg) | Амиди на карбоксилни киселини, лекарствени средства които ги съдържат, тяхното приложение и получаване | |
| NZ807894A (en) | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same | |
| TR200200648T2 (tr) | Farmasötik özelliklere sahip yeni dikarboksilik asit türevleri. | |
| MXPA03010435A (es) | Derivados de oxazol acido carboxilico sustituidos para uso como activadores de proliferacion del peroximosa(ppar-alfa y gama) en el tratamiento de diabetes. | |
| Lee et al. | Caffeoylglycolic and caffeoylamino acid derivatives, halfmers of L-chicoric acid, as new HIV-1 integrase inhibitors | |
| CY1112800T1 (el) | Η χρηση υποκαθιστουμενων κυανοπυρρολιδινων για τη θεραπεια της υπερλιπιδαιμιας | |
| IL151829A (en) | History of carbamate and pharmaceutical preparations containing them | |
| EA200801492A1 (ru) | Фармацевтическое применение замещенных амидов | |
| NZ597375A (en) | Tofa analogs useful in treating dermatological disorders or conditions | |
| IL213397A (en) | Protection module with buffer zone and method for creating it | |
| DE69818286D1 (de) | Pyridylverbindungen und diese enthaltende pharmazeutische zubereitungen | |
| JP2000516197A (ja) | インテグリンレセプターアンタゴニスト | |
| AR035137A1 (es) | Composicion farmaceutica para inhibir metastasis o prevenir recurrencia de tumor maligno | |
| EA008745B1 (ru) | Применение ингибиторов ферментов с активностью аминопептидазы n и/или дипептидилпептидазы iv и фармацевтические композиции на их основе для лечения и профилактики дерматологических заболеваний с себоцитарной гиперпролиферацией и измененными дифференцированными состояниями | |
| KR930019208A (ko) | L-카르니틴 또는 아실 l-카르니틴과 ace-억제제를 함유한 심장혈관질환치료용 약제조성물과 그 치료방법 | |
| TR200100611T2 (tr) | İbuprofen ve domperidon içeren farmasötik kompozisyonlar | |
| MX2025005933A (es) | Derivados de 2-amino-n-(4-amino-3,4-dioxo-1-(2-oxopirrolidin-3-il)butan-2-il)benzamida como inhibidores de la proteasa para el tratamiento o la prevencion de la infeccion por coronavirus | |
| YU58601A (sh) | Derivati fenilalaninola | |
| EE200200098A (et) | Migreeni ravimine alfa-lipohappe või selle derivaatide manustamise abil | |
| DE69828522D1 (de) | Antithrombotische mittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |